Welcome to ehr99.com ! Games Apps News Topics Ranking
Home > News > Accuser in Copyright Spat Gets Review Bombed

Accuser in Copyright Spat Gets Review Bombed

Author : Allison
Jan 08,2026

Schedule I Copyright Infringement Accuser Gets Review Bombed Instead

Schedule I faces copyright infringement allegations, but unexpectedly, fans have retaliated by review-bombing the accuser's games. Explore the details of this controversy and what's next for Schedule I's development.

Latest Developments: Schedule I

Steam Users Review-Bomb Accuser in Schedule I Copyright Dispute

Schedule I Copyright Infringement Accuser Gets Review Bombed Instead

The indie crime simulator Schedule I has been challenged by Movie Games S.A., creators of The Drug Dealer Simulator series, over alleged IP violations. According to an April 3 report by the Polish Press Agency, Movie Games S.A. claims Schedule I replicates their game's narrative, gameplay systems, and UI elements.

While legal proceedings remain pending, the gaming community has taken sides, with Schedule I garnering significant support. The backlash has left The Drug Dealer Simulator series with "Overwhelmingly Negative" and "Mostly Negative" ratings on Steam.

Schedule I Copyright Infringement Accuser Gets Review Bombed Instead

Critical Steam reviews accuse Movie Games S.A. of targeting smaller developers unfairly, noting similar past games went unchallenged. This controversy contrasts with the series' previous acclaim as a standout in crime simulation genres.

Schedule I immerses players in cooperative drug empire management, progressing from street-level dealing to criminal mastery. Since its March 25 Early Access launch, the title has maintained "Overwhelmingly Positive" ratings, ranking as Steam's #2 top-seller behind major AAA titles. SteamDB records show an impressive 459,075 concurrent player peak.

Game8's editorial team found Schedule I delivers an unexpectedly compelling criminal sandbox experience, earning our "Breaking Bad Simulator" endorsement. For our complete Early Access evaluation, see our detailed coverage below.

Latest articles